Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

OncoKB: A Precision Oncology Knowledge Base

Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,783

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430

Non–Small Cell Lung Cancer, Version 4.2024

Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 945

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J., Kim, S., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 681

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

Harrison, P. T., Vyse, S., & Huang, P. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.015 · Cited by 637

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 390

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

Castellanos, E. H., Feld, E., & Horn, L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 322

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Yang, J. C., Schüler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 284

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 259

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Riess, J. W., Gandara, D. R., Frampton, G. M., Madison, R., Peled, N., Bufill, J. A., Dy, G. K., Ou, S.-H. I., Stephens, P. J., McPherson, J. D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.019 · Cited by 240

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1598 · Cited by 231

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Passaro, A., Mok, T. S. K., Peters, S., Popat, S., Ahn, M., & de Marinis, F. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.002 · Cited by 219

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 171

Uncommon EGFR mutations in advanced non-small cell lung cancer

O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153

The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies

Patterson, S. E., Liu, R., Statz, C. M., Durkin, D., Lakshminarayana, A., & Mockus, S. M. (2016) · Human Genomics · doi:10.1186/s40246-016-0061-7 · Cited by 140

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Amelia, T., Kartasasmita, R. E., Ohwada, T., & Tjahjono, D. H. (2022) · Molecules · doi:10.3390/molecules27030819 · Cited by 149

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 130

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Wang, M., Yang, J. C.-H., Mitchell, P. L., Fang, J., Camidge, D. R., Nian, W., Chiu, C.-H., Zhou, J., Zhao, Y., Su, W.-C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1615 · Cited by 133

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131

Rare molecular subtypes of lung cancer

Harada, G., Yang, S., Cocco, E., & Drilon, A. E. D. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00733-6 · Cited by 126

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer

Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., & Zhang, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5820-0 · Cited by 120

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 112

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., Xia, B., Zhu, V. W., Nagasaka, M., Yang, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.014 · Cited by 114

High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods

Su, D., Zhang, D., Chen, K., Lu, J. N., Wu, J., Cao, X., Ying, L., Jin, Q., Ye, Y., Xie, Z., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0591-4 · Cited by 103

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations

Shen, Y.-C., Tseng, G.-C., Tu, C.-Y., Chen, W.-C., Liao, W.-C., Chen, W.-C., Li, C.-H., Chen, H.-J., & Hsia, T.-C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.007 · Cited by 99

Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review

Burnett, H. F., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P. J., & Li, T. M. W. Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247620 · Cited by 91

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1206 · Cited by 88

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Banno, E., Togashi, Y., Nakamura, Y., Chiba, M., Kobayashi, Y., Hayashi, H., Terashima, M., de Velasco, M. A., Sakai, K., Fujita, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12980 · Cited by 87

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations

Bazhenova, L. A., Minchom, A. R., Viteri, S., Bauml, J. M., Ou, S. I., Gadgeel, S. M., Trigo, J. M., Backenroth, D., Li, T. M. W. Y., Londhe, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.020 · Cited by 82

Molecular therapeutic targets in non-small cell lung cancer

Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 85

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Vasconcelos, P. E. N. S., Gergis, C., Viray, H., Varkaris, A. S., Fujii, M., Rangachari, D., VanderLaan, P. A., Kobayashi, I. S., Kobayashi, S. S., & Costa, D. B. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100051 · Cited by 82

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

John, T., Taylor, A., Wang, H., Eichinger, C. S., Freeman, C. S., & Ahn, M. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102080 · Cited by 80

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Piotrowska, Z., Costa, D. B., Oxnard, G. R., Huberman, M., Gainor, J. F., Lennes, I. T., Muzikansky, A., Shaw, A. T., Azzoli, C. G., Heist, R. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy336 · Cited by 79

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

Qin, Y., Jian, H., Tong, X., Wu, X., Wang, F., Shao, Y. W., & Zhao, X. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12710 · Cited by 66

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 70

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 69

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC

van Veggel, B. A. M. H., de Langen, A. J., Hashemi, S. M. S., Monkhorst, K., Heideman, D. A. M., Thunnissen, E., & Smit, E. F. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.012 · Cited by 64

Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations

Ruan, Z., & Kannan, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803152115 · Cited by 59

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

Cardona, A. F., Rojas, L., Zatarain-Barrón, Z. L., Freitas, H., Granados, S. T., Castillo, O., Oblitas, G., Corrales, L., Castro, C. D., Ruíz-Patiño, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.007 · Cited by 62

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 67

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Choudhury, N. J., Schoenfeld, A. J., Flynn, J. R., Falcon, C. J., Rizvi, H. A., Rudin, C. M., Kris, M. G., Arcila, M. E., Heller, G., Yu, H. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4650 · Cited by 60

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Chen, K., Pan, G., Cheng, G., Zhang, F., Xu, Y., Huang, Z., & Fan, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13748 · Cited by 59

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon, S., Kim, Y., Lim, S. W., Cho, J. H., Park, S., Lee, J., Sun, J., Choi, Y., Lee, S., Ahn, J. S., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.151 · Cited by 56

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Chu, Q. S.-C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895756 · Cited by 56

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Steen, N. V. D., Caparello, C., Rolfo, C. D., Pauwels, P., Peters, G. J., & Giovannetti, E. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s97644 · Cited by 55

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision

SOUSA, A. M. D., Silveira, C., Janeiro, A., Malveiro, S., Oliveira, A. R., Felizardo, M., Nogueira, F., Teixeira, E., Martins, J., & Carmo‐Fonseca, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.030 · Cited by 52

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations

Yang, G., Li, J., Xu, H., Sun, Y., Liu, L., Li, H., Yang, L., Zhang, Y., Li, G., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.027 · Cited by 51

Toward a More Precise Future for Oncology

Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

Ou, S. I., Lin, H. M., Hong, J., Yin, Y., Jin, S., Lin, J., Mehta, M., Nguyen, D., & Neal, J. W. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100558 · Cited by 48

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

Shah, M. P., & Neal, J. W. (2022) · Drugs · doi:10.1007/s40265-022-01698-z · Cited by 47

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer

Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations

Wang, J., Lam, D., Yang, J., & Hu, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02952-5 · Cited by 43

EGFR exon 20 insertion mutations in non-small cell lung cancer

Wang, F., Li, C., Wu, Q., & Lu, H. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.10 · Cited by 40

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment

Noronha, V., Choughule, A. B., Patil, V., Joshi, A., Kumar, R., Philip, D. S. J., Banavali, S., Dutt, A., & Prabhash, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133245 · Cited by 41

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer

Leal, J. L., Alexander, M., Itchins, M., Wright, G. M., Kao, S., Hughes, B. G. M., Pavlakis, N., Clarke, S. J., Gill, A. J., Ainsworth, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.009 · Cited by 41

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

on behalf of AME Lung Cancer Collaborative Group, Xu, C., Wang, W., Wang, D., Wang, Q., Pu, X., Zhu, Y., Huang, J., Yu, Z., Cui, Z., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-382 · Cited by 40

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Metro, G., Baglivo, S., Bellezza, G., Mandarano, M., Gili, A., Marchetti, G., Toraldo, M., Molica, C., Reda, M. S., Tofanetti, F. R., et al. (2021) · Genes · doi:10.3390/genes12050679 · Cited by 39

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

Ji, J., Aredo, J. V., Piper‐Vallillo, A. J., Huppert, L. A., Rotow, J. K., Husain, H., Stewart, S., Cobb, R. G., Wakelee, H. A., Blakely, C. M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100459 · Cited by 38

Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Liang, J., Bi, G., Sui, Q., Zhao, G., Zhang, H., Bian, Y., Chen, Z., Huang, Y., Xi, J., Shi, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113771 · Cited by 38

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies

Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38

Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series

Buccoliero, A. M., Giunti, L., Moscardi, S., Castiglione, F., Provenzano, A., Sardi, I., Scagnet, M., Genitori, L., & Caporalini, C. (2022) · Genes · doi:10.3390/genes13040624 · Cited by 41

Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma

Zhang, F., Chen, X., Wei, K., Liu, D., Xu, X., Zhang, X. Y., & Shi, H. (2017) · Medical Science Monitor · doi:10.12659/msm.898297 · Cited by 35

Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

Papini, F., Sundaresan, J., Leonetti, A., Tiseo, M., Rolfo, C. D., Peters, G. J., & Giovannetti, E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103454 · Cited by 35

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Brown, B. P., Zhang, Y., Kim, S., Finneran, P., Yan, Y., Du, Z., Kim, J., Hartzler, A. L., Lenoue-Newton, M. L., Smith, A. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206588119 · Cited by 31

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy

Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.07.001 · Cited by 32

Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

Tu, C., Chen, C., Liao, W.-C., Wu, B., Chen, W., Cheng, W., Hsia, T., Cheng, W., & Chen, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24386 · Cited by 31

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

Nishino, M., Suda, K., Koga, T., Ohara, S., Fujino, T., Soh, J., Tirunagaru, V. G., Vellanki, A., Doebele, R. C., & Mitsudomi, T. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13931 · Cited by 30

Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor

Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32

Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer

Vyse, S., & Huang, P. H. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2016397 · Cited by 33

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer

Huang, W., Li, F., Gong, Y., Zhang, Y., Youngsaye, W., Xu, Y., Zhu, X., Greenfield, M. T., Kohlmann, A., Taslimi, P. M., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129084 · Cited by 29

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer

Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 28

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

Wu, S., Yu, C., Yang, J. C., & Shih, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920946156 · Cited by 27

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions

Stencel, K. M., Chmielewska, I., Milanowski, J., & Ramlau, R. (2021) · Cancers · doi:10.3390/cancers13081829 · Cited by 27

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations

Tamirat, M. Z., Kurppa, K. J., Elenius, K., & Johnson, M. S. (2021) · Cancers · doi:10.3390/cancers13051120 · Cited by 27

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations

Low, J. L., Lim, S. M., Lee, J. B., Cho, B. C., & Soo, R. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146131 · Cited by 25

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 27

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis

Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 24

Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights

Tariq, A., Shoaib, M., Qu, L., Shoukat, S., Nan, X., & Song, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177608 · Cited by 22

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer

Brazel, D., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s337861 · Cited by 22

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab

Piotrowska, Z., Passaro, A., Nguyen, D., Ruiter, G., Soo, R. A., Lee, V. H.-F., Velcheti, V., Tan, D. S. W., Lee, S., Kim, S. H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00763 · Cited by 20

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 21

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study

Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14277 · Cited by 20

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma

Pacini, L., Cabal, V. N., Hermsen, M. A. J. A., & Huang, P. H. (2022) · Cancers · doi:10.3390/cancers14020394 · Cited by 21

Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India

Singh, V., Nambirajan, A., Malik, P. S., Thulkar, S. P., Pandey, R. M., Luthra, K., Arava, S., Ray, R., Mohan, A., & Jain, D. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.038 · Cited by 19

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Chantharasamee, J., Poungvarin, N., Danchaivijitr, P., & Techawatanawanna, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5913-9 · Cited by 21

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

Lan, B., Zhao, N., Du, K., & Leng, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13504 · Cited by 22

Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC

Liu, B., Gao, F., Zhao, H., Yuan, S., Peng, X., Zhang, P., Wang, J., Zhang, T., Duan, M., & Guo, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115590 · Cited by 18

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy

Chelabi, S., Mignard, X., Leroy, K., Monnet, I., Brosseau, S., Théou–Anton, N., Massiani, M.-A., Friard, S., Duchemann, B., Fabre, E., et al. (2021) · Cancers · doi:10.3390/cancers13205132 · Cited by 18

Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy.

Aydıner, A., & Sarı, M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e21212

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy

Chelabi, S., Mignard, X., Leroy, K., Monnet, I., Brosseau, S., Théou–Anton, N., Massiani, M.-A., Friard, S., Duchemann, B., Fabre, E., et al. (2021) · Cancers · doi:10.3390/cancers13205132 · Cited by 18

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Morita, C., Yoshida, T., Shirasawa, M., Masuda, K., Matsumoto, Y., Shinno, Y., Yagishita, S., Okuma, Y., Goto, Y., Horinouchi, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98275-3 · Cited by 30

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

Liao, Y.-T., Wang, L., Sun, R.-L., Yeh, Y., Huang, H.-C., Shen, C., Tseng, Y.-H., Hsiao, T.-H., Chao, H., Luo, Y., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04921-w

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment

Noronha, V., Choughule, A. B., Patil, V., Joshi, A., Kumar, R., Philip, D. S. J., Banavali, S., Dutt, A., & Prabhash, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133245 · Cited by 41